HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ONC
BeOne Medicines Ltd.
ONC's fundamentals are strong: revenue grew 33% and its operating margin rose 14 points to 18%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ONC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ONC's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ONC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 52x | $416 | — |
| Cheap | 62x | $37.70 | -91% |
| Fair | 72x | $43.95 | -89% |
| Expensive | 650x | $396 | -4.8% |
Historical ranges are pointers, not guarantees.
ONC's PE is 52x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ONC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
ONC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ONC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.61 | +1425% |
| Q2 2026 | $0.44 | +$0.57 |
| Q1 2026 | $0.34 | +$0.62 |
| Q4 2025 | $0.19 | +$0.66 |
| Q3 2025 | $0.04 | +$0.67 |
| Q2 2025 | -$0.13 | +$0.26 |
| Q1 2025 | -$0.28 | +$0.30 |
| Q4 2024 | -$0.47 | +$0.18 |
ONC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ONC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ONC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +34% |
| Q2 2026 | $1.7B | +30% |
| Q1 2026 | $1.5B | +35% |
| Q4 2025 | $1.5B | +33% |
| Q3 2025 | $1.4B | +41% |
| Q2 2025 | $1.3B | +42% |
| Q1 2025 | $1.1B | +49% |
| Q4 2024 | $1.1B | +78% |
ONC's revenue has grown year over year for 18 quarters in a row: $1.9B last quarter, up 34% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 22% | +11 points |
| Q2 2026 | 19% | +12 points |
| Q1 2026 | 17% | +16 points |
| Q4 2025 | 12% | +19 points |
| Q3 2025 | 12% | +24 points |
| Q2 2025 | 6.7% | +18 points |
| Q1 2025 | 1% | +36 points |
| Q4 2024 | -7% | +54 points |
ONC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ONC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $473.5M | +34% |
| Q2 2026 | $435.3M | +98% |
| Q1 2026 | $160.5M | +$172.9M |
| Q4 2025 | $379.8M | +$397.1M |
| Q3 2025 | $354.5M | +548% |
| Q2 2025 | $219.8M | +$425.3M |
| Q1 2025 | -$12.3M | +$452.8M |
| Q4 2024 | -$17.3M | +$361.3M |
ONC has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ONC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ONC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +19.6M shares |
| 1 year | +2.4% | +36.2M shares |
| 3 years | +9.7% | +135M shares |
| 5 years | +26% | +319M shares |
| Available history | +52% | +520M shares |
ONC has 1.5B diluted shares, up 2.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ONC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.4x | Net Cash |
| Q2 2026 | -3.7x | Net Cash |
| Q1 2026 | -4.4x | Net Cash |
| Q4 2025 | -6.0x | Net Cash |
| Q3 2025 | -9.5x | Net Cash |
| Q2 2025 | -20.2x | Net Cash |
ONC has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ONC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.6 | Overbought |
| Stochastic | 87.7 | Overbought |
ONC's weekly RSI is 71 (overbought) and its Stochastic is 88 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ONC PE vs Healthcare Sector
| Metric | ONC | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 26x | 103% above |
| PE % | 2 | 29 | 27 pts below |
ONC is trading at 52x earnings, a 103% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ONC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.7 | 10% above |
| 20 week MA | $352.8 | 18% above |
| 50 week MA | $326.9 | 27% above |
| 100 week MA | $298.0 | 40% above |
| 200 week MA | $244.9 | 70% above |
ONC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ONC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $167.2 | $263.7 | +58% |
| 2021 | $263.7 | $268.6 | +1.9% |
| 2022 | $268.6 | $226.1 | -16% |
| 2023 | $226.1 | $180.4 | -20% |
| 2024 | $180.4 | $181.9 | +0.8% |
| 2025 | $181.9 | $312.4 | +72% |
| 2026 YTD | $312.4 | $416.0 | +33% |
ONC has the edge over HIMS on returns for 2026, with the stronger performance.